JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
January 2024
Studysummary In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
Baricitinib, a JAK1/2 inhibitor, has shown promise in treating refractory oral lichen planus, as evidenced by a case report where a patient experienced significant improvement within one month of daily treatment. This case supports the expanding role of baricitinib, already FDA-approved for alopecia areata, in managing various inflammatory dermatologic conditions, including lichen planus.
